Who We Are
AcelaBio (US), Inc. is wholly owned by The Alimentiv Health Trust. Central to the purpose of the Trust is to develop health care innovation through investment in human health initiatives, research and commercial entities, and to foster collaboration and commitment among stakeholders. Thereby, AcelaBio aligns with the Evergreen Principles to grow an enduring company with a long-term view that prioritizes people and purpose.
The Evergreen Principles
Alimentiv Health Trust companies are built on the Evergreen principles that prioritize purpose and growing enduring companies that make a long-term difference in the world for 100+ years.
Evergreen 7Ps Principles
The Evergreen 7Ps™ principles are the defining characteristics of Evergreen. The first three Ps—Purpose, Perseverance, and People First—define the character of the leaders and team. The last four Ps—Private, Profit, Paced Growth, and Pragmatic Innovation—reflect the long-term strategy tenets of an Evergreen business.
Being passionately driven by a compelling vision and mission.
Taking advantage of the ability of closely-held private companies to have a longer-term view, greater confidentiality around strategies, and more operating flexibility than public or exit-oriented businesses.
Having the ambition and the resilience to overcome obstacles and keep pursuing the mission indefinitely into the future.
Not mistaking profit as the purpose of the business; but recognizing it is essential to survival and independence, and the most accurate measure of customer value delivered.
Engaging a workforce of talented associates who excel as a team and are motivated by the mission and the culture, as well as by total compensation, in the belief that, by taking care of them, they will take care of the customers, suppliers, partners, communities, and their families.
Having the discipline to focus on long-term strategy, balance short-term and long-term performance, and grow steadily and consistently from year to year.
Embracing a continuous-improvement process built around taking capital-efficient, calculated risks to innovate creatively within constraints.